Kamer Gündüz
Research Subjects
Kamer Gündüz has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Fatmagül Gülbaşaran
DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ
2 shared publications - Özlem Bilgiç
Department of Dermatology and Venereology, Selcuk University School of Medicine, Konya, Turkey
2 shared publications Arzu Kilic
Faculty of Medicine, Department of Dermatology, Balikesir University, Balikesir, Turkey
1 shared publication- Asli Bilgic
Department of Dermatology and Venereology, Faculty of Medicine Akdeniz University Antalya Turkey
1 shared publication - Aslı Sürer Adanır
Department of Child and Adolescent Psychiatry, Akdeniz University School of Medicine
1 shared publication - Ayca Cordan Yazici
Faculty of Medicine, Medical Microbiology, Mersin University, Mersin, Türkiye
1 shared publication
Latest Publications
- Open Access
- 19 February 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Fibromas discoides múltiplos familiares: características clínicas e breve revisão da literatura
- 19 February 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Open AccessFibromas discoides múltiplos familiares: características clínicas e breve revisão da literatura
- Open Access
- 18 December 2023
- Published by Dokuz Eylul Universitesi Tip Fakultesi Dergisi in Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi
- Vol. 37 (3) , 273-280
Implications from an Ongoing Scabies Outbreak During the COVID-19 Isolation Period: Clues for Controlling Scabies Today
Background: Contrary to the expectation that the number of scabies cases will decrease during the COVID-19 isolation period, scabies has been frequently reported in Turkey. Objective: The aim of this study is to investigate the epidemiological pattern of the scabies outbreak in the context of the pandemic to provide additional information for the control of the devastating scabies outbreak that continues today. Methods: Patients seen in our dermatology clinic before and during the pandemic were evaluated retrospectively. Results: There was no decrease in the rate of scabies patients among all dermatology admissions during the pandemic period (n=143/2912; 4.9%) compared to the pre-pandemic period (n=526/11679; 4.5%) (p=0.348). The high incidence of the new scabies cases before the detection of COVID-19 in the country decreased in the quarantine period. However, the high recurrent admissions of old scabies cases, who already got scabies before pandemic but could not be cured despite repeated treatments, contributed to the ongoing high prevalance of scabies during the pandemic (one-third of all scabies cases seen during the pandemic, n=30/87). Conclusions: We suggest that self-quarantine and increased hygiene during COVID-19 reduced re-infestations and led to a decrease in new cases. Treatment failure of old cases has been observed to contribute to the high prevalence of scabies in the pandemic. Permethrin resistance may have led to inadequate treatment success, given that treatment application errors, which may also lead to treatment failure, are managed with active surveillance in our patient population. Studies addressing permethrin resistance are needed as a priority.
- 18 December 2023
- Published by Dokuz Eylul Universitesi Tip Fakultesi Dergisi in Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi
- Vol. 37 (3) , 273-280
Open AccessImplications from an Ongoing Scabies Outbreak During the COVID-19 Isolation Period: Clues for Controlling Scabies Today
Background: Contrary to the expectation that the number of scabies cases will decrease during the COVID-19 isolation period, scabies has been frequently reported in Turkey. Objective: The aim of this study is to investigate the epidemiological pattern of the scabies outbreak in the context of the pandemic to provide additional information for the control of the devastating scabies outbreak that continues today. Methods: Patients seen in our dermatology clinic before and during the pandemic were evaluated retrospectively. Results: There was no decrease in the rate of scabies patients among all dermatology admissions during the pandemic period (n=143/2912; 4.9%) compared to the pre-pandemic period (n=526/11679; 4.5%) (p=0.348). The high incidence of the new scabies cases before the detection of COVID-19 in the country decreased in the quarantine period. However, the high recurrent admissions of old scabies cases, who already got scabies before pandemic but could not be cured despite repeated treatments, contributed to the ongoing high prevalance of scabies during the pandemic (one-third of all scabies cases seen during the pandemic, n=30/87). Conclusions: We suggest that self-quarantine and increased hygiene during COVID-19 reduced re-infestations and led to a decrease in new cases. Treatment failure of old cases has been observed to contribute to the high prevalence of scabies in the pandemic. Permethrin resistance may have led to inadequate treatment success, given that treatment application errors, which may also lead to treatment failure, are managed with active surveillance in our patient population. Studies addressing permethrin resistance are needed as a priority.
- 31 December 2021
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (4) , 586-591
Psoriasis ve Malignite Birlikteliği: 5 Yıllık Verilerin Retrospektif Analizi
Giriş ve Amaç: Kronik inflamatuar bir hastalık olan psoriasisde, immünolojik değişiklikler ve uzun süreli kullanılan sistemik immünsüpresif tedaviler nedeniyle kanser riskinin arttığı düşünülmektedir. Bu konuda yapılan çalışmalarda çelişkili sonuçlar elde edilmiş, psoriasis ile malignite riski arasındaki ilişki henüz tam olarak aydınlatılamamıştır. Bu çalışmada psoriasisli hastalarda malignite riskinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Manisa Celal Bayar Üniversite Hastanesi elektronik hasta kayıt sisteminden retrospektif tarama yapılarak, 2013 ile 2018 yılları arasında psoriasis tanısı olan 1669 hasta çalışmaya dahil edilmiştir. Aynı dönemde Dermatoloji polikliniğine başvuran ve psoriasis tanısı olmayan 3870 hasta kontrol grubu olarak değerlendirilmiştir. Her iki grupta, dermatolojik tanı aldıkları tarihten 1 ay sonrasından başlayarak kanserin tipi ve kanser tanısı aldıkları zaman kaydedilmiştir. Bulgular: Psoriasis ve kontrol gruplarının yaş ortalamaları sırasıyla 40,33±17,58 ve 40,22±16,91 olarak bulunmuştur. Psoriasis grubunun %47,5’i (n=793), kontrol grubunun %48,9’u (n=1892) kadınlardan oluşmaktaydı. Kanser bulunma sıklığı psoriasis grubunda %3,62, kontrol grubunda %4,25 olup, istatistiksel olarak anlamlı farklılık saptanmamıştır. Psoriasisli hasta ve kontrol grubu arasında, kanser tanı yaşı, kanserli hastaların cinsiyet dağılımı açısından anlamlı farklılık bulunmamıştır. Herhangi bir immünsupresif ilaç öyküsü bulunmasının genel olarak, ya da ilaçlardan herhangi birinin psoriasis hastalarında kanser riski üzerine anlamlı etkisi saptanmamıştır. Sonuç: Sonuç olarak, beş yıllık takipte psoriasise ya da psoriasis tedavisinde kullanılan ilaçlara bağlı olarak artmış bir malignite riski saptanmamıştır. Retrospektif bir çalışma olduğu için kanser riskini artırabilecek her parametrenin tam kontrolünün sağlanamaması bu çalışmanın kısıtlılığıdır. Kısa süreli tedavi alan hastaların da birlikte analiz edilmesi, uzun süre tedavi alan hastalarda kanser riskini istatistiksel olarak maskelemiş olabilir. Bu nedenle uzun yıllar sürecek şekilde planlanmış, prospektif randomize kontrollü çalışmaların gerçekleştirilmesine ihtiyaç vardır.
- 31 December 2021
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (4) , 586-591
Psoriasis ve Malignite Birlikteliği: 5 Yıllık Verilerin Retrospektif Analizi
Giriş ve Amaç: Kronik inflamatuar bir hastalık olan psoriasisde, immünolojik değişiklikler ve uzun süreli kullanılan sistemik immünsüpresif tedaviler nedeniyle kanser riskinin arttığı düşünülmektedir. Bu konuda yapılan çalışmalarda çelişkili sonuçlar elde edilmiş, psoriasis ile malignite riski arasındaki ilişki henüz tam olarak aydınlatılamamıştır. Bu çalışmada psoriasisli hastalarda malignite riskinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Manisa Celal Bayar Üniversite Hastanesi elektronik hasta kayıt sisteminden retrospektif tarama yapılarak, 2013 ile 2018 yılları arasında psoriasis tanısı olan 1669 hasta çalışmaya dahil edilmiştir. Aynı dönemde Dermatoloji polikliniğine başvuran ve psoriasis tanısı olmayan 3870 hasta kontrol grubu olarak değerlendirilmiştir. Her iki grupta, dermatolojik tanı aldıkları tarihten 1 ay sonrasından başlayarak kanserin tipi ve kanser tanısı aldıkları zaman kaydedilmiştir. Bulgular: Psoriasis ve kontrol gruplarının yaş ortalamaları sırasıyla 40,33±17,58 ve 40,22±16,91 olarak bulunmuştur. Psoriasis grubunun %47,5’i (n=793), kontrol grubunun %48,9’u (n=1892) kadınlardan oluşmaktaydı. Kanser bulunma sıklığı psoriasis grubunda %3,62, kontrol grubunda %4,25 olup, istatistiksel olarak anlamlı farklılık saptanmamıştır. Psoriasisli hasta ve kontrol grubu arasında, kanser tanı yaşı, kanserli hastaların cinsiyet dağılımı açısından anlamlı farklılık bulunmamıştır. Herhangi bir immünsupresif ilaç öyküsü bulunmasının genel olarak, ya da ilaçlardan herhangi birinin psoriasis hastalarında kanser riski üzerine anlamlı etkisi saptanmamıştır. Sonuç: Sonuç olarak, beş yıllık takipte psoriasise ya da psoriasis tedavisinde kullanılan ilaçlara bağlı olarak artmış bir malignite riski saptanmamıştır. Retrospektif bir çalışma olduğu için kanser riskini artırabilecek her parametrenin tam kontrolünün sağlanamaması bu çalışmanın kısıtlılığıdır. Kısa süreli tedavi alan hastaların da birlikte analiz edilmesi, uzun süre tedavi alan hastalarda kanser riskini istatistiksel olarak maskelemiş olabilir. Bu nedenle uzun yıllar sürecek şekilde planlanmış, prospektif randomize kontrollü çalışmaların gerçekleştirilmesine ihtiyaç vardır.
- Open Access
- 26 March 2021
- Published by Academician Publishing
- p. 12-24
Topikal Retinoidler
A vitamininin doğal metaboliti olan tretinoin, aynı zamanda sentezlenen ilk retinoiddir. Birinci jenerasyon sentetik non-aromatik retinoidler grubunda yer alır. Tretinoin topikal olarak çeşitli dermatolojik hastalıkların tedavisinde, sistemik olarak ise akut promiyelositik lösemi tedavisinde kullanılmaktadır. Topikal tretinoinin akne vulgaris ve fotoyaşlanmaya bağlı deri değişikliklerinin tedavisinde kullanımı onaylanmıştır. Bu iki endikasyon dışında topikal tretinoin pek çok dermatolojik hastalığın (melazma, aktinik keratoz, displastik nevus, stria, skar, alopesi, siğiller, keratozis pilaris, nevus komedonikus, perforan hastalıklar, porokeratoz, vb) tedavisinde kullanılmaktadır.
- 26 March 2021
- Published by Academician Publishing
- p. 12-24
Open AccessTopikal Retinoidler
A vitamininin doğal metaboliti olan tretinoin, aynı zamanda sentezlenen ilk retinoiddir. Birinci jenerasyon sentetik non-aromatik retinoidler grubunda yer alır. Tretinoin topikal olarak çeşitli dermatolojik hastalıkların tedavisinde, sistemik olarak ise akut promiyelositik lösemi tedavisinde kullanılmaktadır. Topikal tretinoinin akne vulgaris ve fotoyaşlanmaya bağlı deri değişikliklerinin tedavisinde kullanımı onaylanmıştır. Bu iki endikasyon dışında topikal tretinoin pek çok dermatolojik hastalığın (melazma, aktinik keratoz, displastik nevus, stria, skar, alopesi, siğiller, keratozis pilaris, nevus komedonikus, perforan hastalıklar, porokeratoz, vb) tedavisinde kullanılmaktadır.
- 1 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (2) , e14835
Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers?
Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating skin disease. Recent studies showed that inflammatory biomarkers, such as neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR), Lymphocyte/HDL ratio (LHR), Neutrophil/HDL ratio (NHR), and Monocyte/HDL ratio (MHR) are an indicator of inflammatory diseases and may be associated with disease severity and disease activity. To investigate NLR, PLR, LHR, NHR, and MHR in HS patients. In addition, to compare erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), complete blood count, leukocyte profile, and biochemical parameters between the control and the patient group. Clinical and biochemical data of patients and healthy subjects were collected from medical records, retrospectively. In total, 166 patients with HS and 124 control subjects were included. We found no significant difference in NLR ( P = .207) and PLR ( P = .257). LHR ( P < .001), NHR ( P < .001), and MHR ( P < .001) were significantly higher in the patient group. No positive correlation was found between any of these markers and disease severity according to Hurley staging system. However, MCV (Mean corpuscular volume), RDW (Red cell distribution width), and CRP showed a significant positive correlation with disease severity. Among these markers, only MHR was positively correlated with disease duration. Our study shows that CRP still maintains its value for HS patients compared to new inflammation markers. Unlike the studies in other inflammatory diseases, no significant relationship was found with most of these inflammatory parameters. MHR may be more useful in patients with HS as an indicator of inflammation compared to other parameters.
- 1 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (2) , e14835
Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers?
Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating skin disease. Recent studies showed that inflammatory biomarkers, such as neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR), Lymphocyte/HDL ratio (LHR), Neutrophil/HDL ratio (NHR), and Monocyte/HDL ratio (MHR) are an indicator of inflammatory diseases and may be associated with disease severity and disease activity. To investigate NLR, PLR, LHR, NHR, and MHR in HS patients. In addition, to compare erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), complete blood count, leukocyte profile, and biochemical parameters between the control and the patient group. Clinical and biochemical data of patients and healthy subjects were collected from medical records, retrospectively. In total, 166 patients with HS and 124 control subjects were included. We found no significant difference in NLR ( P = .207) and PLR ( P = .257). LHR ( P < .001), NHR ( P < .001), and MHR ( P < .001) were significantly higher in the patient group. No positive correlation was found between any of these markers and disease severity according to Hurley staging system. However, MCV (Mean corpuscular volume), RDW (Red cell distribution width), and CRP showed a significant positive correlation with disease severity. Among these markers, only MHR was positively correlated with disease duration. Our study shows that CRP still maintains its value for HS patients compared to new inflammation markers. Unlike the studies in other inflammatory diseases, no significant relationship was found with most of these inflammatory parameters. MHR may be more useful in patients with HS as an indicator of inflammation compared to other parameters.
- Open Access
- 1 January 2020
- Published by XMLink in Annals of Dermatology
- Vol. 32 (3) , 181-188
Internalized Stigma in Pediatric Psoriasis: A Comparative Multicenter Study
Alpsoy E, et al. Ann Dermatol. 2020 Jun;32(3):181-188. https://doi.org/10.5021/ad.2020.32.3.181
- 1 January 2020
- Published by XMLink in Annals of Dermatology
- Vol. 32 (3) , 181-188
Open AccessInternalized Stigma in Pediatric Psoriasis: A Comparative Multicenter Study
Alpsoy E, et al. Ann Dermatol. 2020 Jun;32(3):181-188. https://doi.org/10.5021/ad.2020.32.3.181
- 21 December 2018
- Published by Wiley in International Journal of Dermatology
- Vol. 58 (6) , 722-728
Systemic comorbidities associated with rosacea: a multicentric retrospective observational study
Background: Once considered a disorder limited to the skin, rosacea is now known to be associated with systemic disorders. The aim of this study was to determine what systemic comorbidities accompany rosacea and to determine the relationship between the type, severity, and duration of rosacea, and the presence of and type of systemic comorbidities.Methods: This retrospective multicenter study was conducted by the Turkish Society of Dermatology Acne Study Group. Thirteen dermatology clinics throughout Turkey participated in the study. A structured physician‐administered questionnaire was used to collect patient demographics, clinical findings, and lifestyle data. The principal rosacea subtype, physician global assessment of severity, and duration of rosacea were recorded. Physicians recorded each participant's medical history, including current and past comorbidities, duration of any such comorbidity, and the use of medications to treat any comorbidities.Results: The study included 1,195 rosacea patients and 621 controls without rosacea aged 18–85 years. As compared to the controls, more of the rosacea patients had respiratory tract, gastrointestinal system, and metabolic and hepatobiliary system disorders in a rosacea's severity‐ and duration‐dependent manner.Conclusion: Clinicians must be aware of the potential for systemic comorbidities in rosacea patients, which becomes more likely as disease duration and severity increase.
- 21 December 2018
- Published by Wiley in International Journal of Dermatology
- Vol. 58 (6) , 722-728
Systemic comorbidities associated with rosacea: a multicentric retrospective observational study
Background: Once considered a disorder limited to the skin, rosacea is now known to be associated with systemic disorders. The aim of this study was to determine what systemic comorbidities accompany rosacea and to determine the relationship between the type, severity, and duration of rosacea, and the presence of and type of systemic comorbidities.Methods: This retrospective multicenter study was conducted by the Turkish Society of Dermatology Acne Study Group. Thirteen dermatology clinics throughout Turkey participated in the study. A structured physician‐administered questionnaire was used to collect patient demographics, clinical findings, and lifestyle data. The principal rosacea subtype, physician global assessment of severity, and duration of rosacea were recorded. Physicians recorded each participant's medical history, including current and past comorbidities, duration of any such comorbidity, and the use of medications to treat any comorbidities.Results: The study included 1,195 rosacea patients and 621 controls without rosacea aged 18–85 years. As compared to the controls, more of the rosacea patients had respiratory tract, gastrointestinal system, and metabolic and hepatobiliary system disorders in a rosacea's severity‐ and duration‐dependent manner.Conclusion: Clinicians must be aware of the potential for systemic comorbidities in rosacea patients, which becomes more likely as disease duration and severity increase.